Open access
Oct 2026
Safety, tolerability, and pharmacokinetics (PK) of luspatercept (LUSPA) at increased injection volumes (up to 2 mL) in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) who require red blood cell (RBC) transfusions: Results from MAXILUS.
531 Background: LUSPA is approved for anemia in adults with LR-MDS who are erythropoiesis-stimulating agent (ESA)-naive or have had prior ESA failure and require RBC transfusions. At previously FDA-approved 1.2 mL syringe volume cap, LUSPA 1.75 mg/kg dosing requires multiple subcutaneous (SC) injections across...
Ali McBride, Krzysztof Mądry, Luke Fletcher et al.
· JCO Oncology Practice · 0 citations